Phenylalanine blood levels and clinical outcomes in phenylketonuria: a systematic literature review and meta-analysis (Q36859872)

16 August 2017

0 references

Phenylalanine blood levels and clinical outcomes in phenylketonuria: a systematic literature review and meta-analysis (English)

1 reference

16 August 2017

1 reference

1 reference

1 reference

Susan E Waisbren

1

1 reference

16 August 2017

Kay Noel

2

1 reference

16 August 2017

Kyle Fahrbach

3

1 reference

16 August 2017

Catherine Cella

4

1 reference

16 August 2017

Diana Frame

5

1 reference

16 August 2017

Alex Dorenbaum

6

1 reference

16 August 2017

Harvey Levy

7

1 reference

16 August 2017

25 June 2007

1 reference

Molecular Genetics and Metabolism

16 August 2017

1 reference

16 August 2017

92

1 reference

16 August 2017

63-70

1 reference

16 August 2017

1-2

1 reference

PAHdb: a locus-specific knowledgebase.

16 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.05.006

Neurological aspects of adult phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.05.006

Tetrahydrobiopterin as an alternative treatment for mild phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.05.006

Development of the phenylketonuria screening programme in Estonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.05.006

A longitudinal study of phenylketonuria based on the data of the Budapest Screening Center

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.05.006

Phenylketonuria in a low incidence population: molecular characterisation of mutations in Finland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.05.006

Follow-up study of a nation-wide neonatal metabolic screening program in Japan. A collaborative study group of neonatal screening for inborn errors of metabolism in Japan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.05.006

National Institutes of Health Consensus Development Conference Statement: phenylketonuria: screening and management, October 16-18, 2000.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.05.006

Effect of age at loss of dietary control on intellectual performance and behavior of children with phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.05.006

Normal clinical outcome in untreated subjects with mild hyperphenylalaninemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.05.006

Phenylketonuria in adulthood: a collaborative study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.05.006

Acceptability of a new modular protein substitute for the dietary treatment of phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.05.006

Comments on diet and compliance in phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.05.006

Maternal PKU: strategies for dietary treatment and monitoring compliance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.05.006

Psychosocial factors in maternal phenylketonuria: women's adherence to medical recommendations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.05.006

How practical are recommendations for dietary control in phenylketonuria?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.05.006

Systematic reviews: synthesis of best evidence for clinical decisions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.05.006

Meta-analysis in clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.05.006

Plasma arachidonic acid and serum thromboxane B2 concentrations in phenylketonuric children negatively correlate with dietary compliance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.05.006

Can measures of infant habituation predict later intellectual ability?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.05.006

To what extent is failure to thrive in infancy associated with poorer cognitive development? A review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.05.006

Wechsler subscale IQ and subtest profile in early treated phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.05.006

Neurological outcome in adult patients with early-treated phenylketonuria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.05.006

The dynamics of brain concentrations of phenylalanine and its clinical significance in patients with phenylketonuria determined by in vivo 1H magnetic resonance spectroscopy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.05.006

Long-term follow-up of patients treated for phenylketonuria (PKU). Results from the Prague PKU Center.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.05.006

Subclinical visual impairment in phenylketonuria. A neurophysiological study (VEP-P) with clinical, biochemical, and neuroradiological (MRI) correlations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.05.006

School performance and intellectual outcome in adolescents with phenylketonuria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.05.006

Behavioural and emotional problems in early-treated adolescents with phenylketonuria in comparison with diabetic patients and healthy controls.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.05.006

Regression of neuropsychological deficits in early-treated phenylketonurics during adolescence.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.05.006

Untreated non-phenylketonuric-hyperphenylalaninaemia: intellectual and neurological outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.05.006

Intelligence and quality of dietary treatment in phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.05.006

Effect on intelligence of relaxing the low phenylalanine diet in phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.05.006

Development of intelligence in early treated phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.05.006

Short-term dietary interventions in children and adolescents with treated phenylketonuria: effects on neuropsychological outcome of a well-controlled population.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.05.006

Recommendations on the dietary management of phenylketonuria. Report of Medical Research Council Working Party on Phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.05.006

Rationale for the German recommendations for phenylalanine level control in phenylketonuria 1997.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.05.006

Long-term follow up of patients with classical phenylketonuria after diet relaxation at 5 years of age. The Paris Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.05.006

Termination of dietary treatment in phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.05.006

Effect of stopping low-phenylalanine diet on intellectual progress of children with phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.05.006

Prefrontal cortex cognitive deficits in children treated early and continuously for PKU.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.05.006

Sustained attention and inhibition of cognitive interference in treated phenylketonuria: associations with concurrent and lifetime phenylalanine concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.05.006

Neuropsychology of early-treated phenylketonuria: specific executive function deficits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.05.006

Effects of concurrent phenylalanine levels on sustained attention and calculation speed in patients treated early for phenylketonuria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.05.006

Summary of findings from the United States Collaborative Study of children treated for phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.05.006

Timing is everything: executive functions in children exposed to elevated levels of phenylalanine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.05.006

Molecular analysis of PKU in Ireland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.05.006

10.1016/J.YMGME.2007.05.006

7 January 2021

Identifiers

DOI

1 reference

16 August 2017

1 reference